Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and Pralatrexate

Trial Profile

Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and Pralatrexate

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Pralatrexate (Primary)
  • Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Aug 2017 Planned initiation date changed from 10 Sep 2017 to 1 Oct 2017.
    • 09 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top